Article

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma.

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232-5505, USA.
Bone marrow transplantation (Impact Factor: 3). 02/2011; 47(1):82-7. DOI: 10.1038/bmt.2011.29
Source: PubMed

ABSTRACT Early lymphocyte recovery following auto-SCT for non-Hodgkin's lymphoma (NHL) has been reported to be associated with improved outcome. The significance of early lymphocyte recovery following a stem cell transplant in NHL subtype diffuse large B-cell lymphoma (DLBCL) in the rituximab era remains unclear. Patients who underwent an auto-SCT at our institution for DLBCL during the time period 1998-2008 (n=115) were included in the study. Patient characteristics were well-balanced in both rituximab naïve and rituximab-exposed groups. Prior rituximab therapy did not affect lymphocyte recovery on day 14 or day 28. Lymphocyte recovery on day 14 and day 28 and prior rituximab had no impact on survival after auto-SCT for DLBCL, despite early benefit. Other factors such as age, stage at presentation, number of salvage regimens, mobilization procedure, conditioning regimen, pre-transplant radiation therapy and pre-transplant disease status had no impact on survival. Our data showed that the survival benefit with early lymphocyte recovery and prior rituximab seen in previous reports may be lost with longer follow-up. Prior rituximab therapy does not appear to influence the lymphocyte count at days 14 and 28 following auto-SCT. Our findings suggest that future trials should consider manipulating the immune system as a post transplant intervention to improve long-term outcome.

0 Bookmarks
 · 
53 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the well-defined role of autologous haematopoietic stem cell transplantation (autoHCT) in the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL), relapse remains the main cause of transplant failure. We retrospectively evaluated long-term outcome and prognostic factors affecting survival of 132 patients with refractory (n = 89) or relapsed HL (n = 43) treated with autoHCT following modified BEAM. With a median follow-up of 68 months, the 10-year overall survival (OS) and progression-free survival (PFS) were 76 and 66 %, respectively. The 10-year cumulative incidence of second malignancies was 7 %. In multivariate analysis, age ≥45 years, more than one salvage regimens and disease status at transplant worse than CR were factors predictive for poor OS. In relapsed HL, age at transplant, response duration (<12 vs. ≥12 months) and the number of salvage regimens were independent predictors for PFS. In the refractory setting, disease status at autoHCT and the number of salvage regimens impacted PFS. The number of risk factors was inversely correlated with PFS in both relapsed and refractory HL (p = 0.003 and <0.001, respectively). The median PFS for patients with >1 risk factor in the relapsed and refractory setting was 5 and 11 months, respectively, in comparison with the median PFS not reached for patients with 0-1 risk factor in both settings. We conclude that high proportion of patients with relapsed/refractory HL can be cured with autoHCT. However, the presence of two or more risk factors helps to identify poor prognosis patients who may benefit from novel treatment strategies.
    Medical Oncology 09/2013; 30(3):611. · 2.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: A phase I trial of infusing anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) armed activated T cells (aATC) was conducted in high-risk/refractory non-Hodgkins Lymphoma (NHL) patients to determine whether aATC infusions are safe, affect immune recovery, and induce an anti-lymphoma effect. METHOD: Ex vivo expanded ATC from 12 patients were armed with CD20Bi, cryopreserved, and infused after autologous stem cell transplant (SCT). Patients underwent SCT after high dose chemotherapy and aATC infusions were started on day +4. The patients received 1 infusion of aATC/week for 4 weeks after SCT with doses of 5, 10, 15, and 20 x 10(9). RESULTS: aATC infusions were safe and did not impair engraftment. The major side effects were chills, fever, hypotension and fatigue. The mean number of IFN-γ EliSpots directed at lymphoma (DAUDI, p = 0.0098) and NK targets (K562, p < 0.0051) and the mean specific cytotoxicity directed at DAUDI (p=0.037) and K562 (p =0.002) from Pre SCT to post SCT were significantly higher. The increase in IFN-γ EliSpots from pre SCT to post SCT in patients who received armed ATC after SCT were significantly higher than those in patients who received SCT alone (p=0.02). Serum IL-7, IL-15, MIP-1β, IP-10, MIP-1α, and MIG increased within hours after infusion. Polyclonal and specific antibodies were near normal 3 months after SCT. CONCLUSIONS: aATC infusions were safe, increased innate and specific anti-lymphoma cell immunity without impairing antibody recovery after SCT.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 03/2013; · 3.15 Impact Factor
  • Cytotherapy 09/2011; 13(8):900-2. · 3.06 Impact Factor

Full-text

Download
0 Downloads
Available from